CID

Lerma de Villada, Mexico
Lerma de Villada, Mexico
SEARCH FILTERS
Time filter
Source Type

News Article | May 26, 2017
Site: www.eurekalert.org

...or whether it merits an inquest, even when faced with identical case information A FORMER top detective turned University of Huddersfield researcher has published his findings that coroners in England and Wales are seemingly unable to agree on what caused a person's death or whether it merits an inquest, even when faced with identical case information. There is therefore an urgent need for a new consensus, which could save lives, argues Dr Maxwell Mclean. Now an Affiliate of the University's Secure Societies Institute, he is a former Detective Chief Superintendent and Head of West Yorkshire's CID and Homicide Team. After his years investigating death and serious crime, he decided to conduct PhD research into inconsistency among coroners, a topic in which he developed an interest during his police career. He was awarded his PhD in 2015 and his latest publication is the article titled Contradictory coroners? Decision-making in death investigations, in the Journal of Clinical Pathology. Dr Mclean argues that the wide variability in decision-making and practice has important implications for bereaved families and for the prevention of avoidable deaths. He calls for a national coroner consensus as a matter of urgency. Around 507,000 people die in England and Wales every year. Nearly half (45%) of these deaths are reported to coroners, who investigate those believed to be violent, unnatural, or of unknown cause, to find out the identity of the deceased and the circumstances of his or her death. But national data show differences in the rates at which coroners choose to investigate deaths and how often they record certain conclusions. And it is unclear why there are so many inconsistencies in coroners' decision-making and practice. So Maxwell Mclean invited all 96 senior coroners in England and Wales to take part in an online task and reach a verdict on three fictitious scenarios that were typical of reported deaths coming to inquest. The scenarios included a complication arising after surgery (scenario 1): a combination of trauma and natural disease (scenario 2); and an infectious disease (scenario 3). Every participant was given the same information, but it was randomly displayed so that it appeared differently for each of them. This was to find out if there were any differences in the way in which the coroners accessed the case information, as assessed by sequence, frequency, and how difficulty in reaching a decision. There was little consensus on the conclusions reached among the 35 coroners who completed the task, despite the fact that they had been given identical information for all three scenarios. Scenarios 1 and 2 generated four different conclusions, ranging from death from natural causes, to death by misadventure/accident. And some said there was not enough information to make a decision. Eight different conclusions were reached for scenario 3, including death from natural causes, death by accident/misadventure, death by drug misuse and an open verdict. Coroners would sometimes adopt polar opposites in their interpretation of the facts. For example, comments for scenario 2 included: "The osteoporosis was the underlying natural disease which resulted in the fracture and set in motion the train of events that led to the death" (natural causes); "even though there is osteoporosis, there is still the trauma which caused the fracture" (accidental death). Analysis of the software data on access showed that the coroners approached the case information in a similar way, tended to agree on what was important, did not differ by gender or experience, and found little difficulty in reaching a decision. But they still arrived at widely different outcomes, a disparity that seems to arise from coroners' personal interpretation of facts, suggests Dr Mclean. "If coroners cannot agree on what caused a person's death, or whether the death was even reportable or not, then the desired prevention of future deaths becomes a difficult task. This is how we keep people alive," he asserts. "A national coroner consensus to achieve a shared inference from available evidence is urgently needed."


News Article | May 23, 2017
Site: www.marketwired.com

Johns Hopkins Genomics at The Johns Hopkins University, Georgia Cancer Center at Augusta University, CID Research, Progenity, Inc., DarwinHealth, Inc., and Channing Division of Network Medicine at Brigham and Women's Hospital Among New Qumulo Customers; Qumulo Reports More Than 2X Growth in Petabytes Shipped to Life Sciences and Medical Research Customers in 12 Months SEATTLE, WA--(Marketwired - May 23, 2017) - Qumulo, the leader in modern scale-out storage, today announced that leading life sciences and medical research institutions are choosing Qumulo to accelerate their data-intensive workflows, including cancer and infectious disease research, genomics, bioinformatics, proteomics, microscopy and big data. Johns Hopkins Genomics (including the NIH CIDR Program at The Johns Hopkins University), the Center for Infectious Disease Research, Georgia Cancer Center at Augusta University, Channing Division of Network Medicine at Brigham and Women's Hospital, Progenity, Inc., and DarwinHealth, Inc. have joined the rapidly growing number of customers turning to Qumulo to speed discovery of new medical breakthroughs. "Workflows in life sciences are characterized by massive volumes of machine-generated file data pipelined into downstream processes for analysis," said Peter Godman, co-founder and CTO of Qumulo. "The rapid growth of file-based storage and processing requirements compounded by limited IT resources has created a scalability crisis for life sciences and medical research organizations. Efficient, high-performance processing of file-based data is at the heart of innovation and discovery in life sciences -- something legacy file storage cannot provide. Qumulo has become the clear answer for data-intensive life sciences workflows." Qumulo accelerates data-intensive workflows in life science and medical research including cancer and infectious disease research and microscopy. Analysis of tissue and cancer tumor studies generates millions to billions of small files, and the expanding bio-repository file data requirements are outgrowing the capacity of legacy storage. Qumulo's modern scale-out storage provides researchers with faster analysis times and IT staff with real-time visibility and control at scale. The high performing, cost-effective storage platform allows for a single file system to be shared across groups to prevent long wait times previously associated with sharing large data sets among groups. Qumulo is the modern replacement for legacy scale-out storage architectures that cannot keep up with modern data requirements. Ron Hood, director of IT at the Center for Infectious Disease Research said, "Qumulo Core's modern architecture is built for the future and that's what closed the deal for us. We didn't want to spend our budget on legacy scale-out storage systems that are obsolete or will be in two to three years. Qumulo supports our needs today and well into the future, so that we can achieve faster times to analysis for our most critical research." Microscopy systems often generate image data sets as large as 1TB per experiment. Those images are stored and accessed for processing and analysis from client computers running operating systems such as Windows, macOS and Linux. The sequencing data is a widely varied collection of files ranging in size from a few kilobytes, often numbering in the millions to billions, up to large image files that can be 50 GB each. Qumulo is the ideal solution for this workload, providing high scalability, high performance, fast access to files across the entire range for processing and analysis, storage of billions of files and support for mixed file workloads. Qumulo Core was designed from the ground up for the new era of multi-petabyte data scale on premises and in the cloud. Qumulo Core stores tens of billions of files with scalable throughput and is the only product that provides real-time visibility and control for file systems at petabyte scale. Storage administrators and life sciences researchers can instantly see usage, activity and throughput at any level of the unified directory structure, no matter how many files in the file system, allowing them to pinpoint problems and effectively manage how storage is used by analysis pipelines. In addition, a Qumulo Core storage cluster can be installed and deployed in minutes without specialized IT expertise. Qumulo's publicly announced life sciences customers include: Carnegie Institution for Science, CID Research, Channing Division of Network Medicine at Brigham and Women's Hospital, DarwinHealth, Inc., Georgia Cancer Center at Augusta University, Institute for Health Metrics and Evaluation (IHME) at University of Washington, Johns Hopkins Genomics at The Johns Hopkins University, Progenity, Inc., UConn Health, University of Utah Scientific Computing and Imaging (SCI) Institute. Connect with Qumulo at Bio-IT World Qumulo will be featured in booth #333 at Bio-IT World, taking place May 23-25 in Boston. The company will sponsor, exhibit, and demonstrate the power of Qumulo Core for life sciences workflows. In addition, Peter Godman, the company's co-founder and CTO, will present on Kickstarting Breakthroughs in Life Sciences with Intelligent, Next-Generation Scale-Out Storage on Thursday, May 25 at 11:40am ET. To schedule one-on-one meetings with Qumulo representatives at Bio-IT World, send an email to info@qumulo.com or schedule online here. Suggested Tweet: Life Sciences and Medical Research Turning to @Qumulo For Modern Scale-Out File #Storage http://qumulo.com/4061 About Qumulo Qumulo enables enterprises to manage and store billions of digital assets with real-time visibility and control built directly into the file system. Going past the design limitations of legacy NAS, Qumulo Core is modern scale-out storage for the new era of multi-petabyte data footprints on premises and in the cloud. It is used by the leaders of data-intensive industries. Founded in 2012 by the inventors of scale-out NAS, Qumulo has attracted a world-class team of innovators, investors and partners. For more information, visit www.qumulo.com.


News Article | June 22, 2017
Site: www.prweb.com

The Silicon Valley Asia Technology Alliance (SVATA), a nonprofit dedicated to fostering global cross-collaborations between Silicon Valley and Southeast Asia, today announced that Sonita Lontoh, founding partner, will speak at the 4th Congress of Indonesian Diaspora, which will be opened by the 44th U.S. President Barack Obama, in Jakarta, Indonesia, on July 1. From the gold rush to the digital age, the spirit of innovation is alive and well in Silicon Valley. SVATA looks for concrete ways to leverage this American spirit of ingenuity to foster global entrepreneurship and innovation as tools to help emerging countries and people in Southeast Asia, especially Indonesia, tackle our most pressing challenges and create opportunities for the betterment of all. Ms. Lontoh, a Silicon Valley Internet of Things Executive and an Indonesian diaspora, will speak on topics focusing on innovation, technology and entrepreneurship. Last summer, Ms. Lontoh was invited by the White House to speak at President Barack Obama’s Global Entrepreneurship Summit in Silicon Valley on ways to foster more global cross-collaborations between Silicon Valley and Southeast Asia. Fittingly, this summer, Ms. Lontoh will speak on the same topic in Southeast Asia. The Congress of Indonesian Diaspora is a biennial gathering of the global Indonesian diaspora and the Indonesian people. It is estimated that there are six to eight million Indonesian diaspora around the world. As the world is becoming more global and interconnected, these diaspora are helping to act as the interlocutors to help connect and increase global cross-collaborations between their new countries of residence and Indonesia, the 4th largest country in the world with a population of more than 250 million people and a fast-growing economy. This year, the 4th Congress (CID4) will be held in Jakarta, the capital of Indonesia, on July 1-4. The Congress will feature powerful and prominent speakers, including the 44th U.S President Barack Obama, members of the Indonesian governments, and prominent Indonesians and Indonesian diaspora. The Congress will also focus on such important topics as human rights, innovation, entrepreneurship and economic developments and is expected to be attended by more than 10,000 attendees. “We seek to harness the power of the Indonesian diaspora to inspire, empower, and help with Indonesia’s developments. As we welcome all to this 4th Congress, I look forward to the thought-provoking and informative discussions during the event that I hope will inspire and empower the young generations of Indonesians to help the country move up the ladder in the 21st century,” said Dr. Dino Patti Djalal, chairman of the board of the Indonesian Diaspora Network Global (IDNG) “I am humbled and honored for the opportunity to speak at the Congress. As an Indonesian American female technology executive and entrepreneur, I always look for ways to increase global cross collaboration in technology, innovation and entrepreneurship, between the United States and Southeast Asia, especially Indonesia,” said Sonita Lontoh, managing partner, SVATA. About SVATA SVA Technology Alliance (SVATA) is a Silicon Valley-based nonprofit whose mission is to connect and spur global cross collaborations between the tech ecosystem of Silicon Valley and Southeast Asia. SVATA collaborates with top Silicon Valley’s technology entrepreneurs, venture capitalists and incubators/accelerators to create an ecosystem that can help high-growth technology companies from emerging markets succeed on a global level. To learn more, visit http://www.svatechnology.com About CID4 CID4 aims to showcase inspiring Indonesian diaspora from around the world to help create new opportunities for partnerships and collaborations with their Indonesian counterparts and each other, to help address some of the most intractable development challenges. Hosting CID4 in Jakarta will highlight Indonesia’s creative and dynamic spirit and allow diaspora and Indonesians alike to discuss solutions and opportunities that exist globally. In bringing CID4 back to Indonesia, we highlight our commitment to building bridges to help us tackle global challenges together. To learn more, visit http://www.cid4.info


News Article | May 24, 2017
Site: www.prfire.com

Millions of euros from Russia to Britain, via Cyprus The activities of Russian oligarch Alexander Shchukin have thrown Cyprus into the whirlpool of international media. According to media reports, the Russian Authorities have asked, through Interpol, for details of Shchukin’s bank accounts and offshore companies, through which some €500 million appear to have been transferred from Russia to Britain. The international media have implicated the Russian tycoon, who is currently under house arrest, in cases of conflict of interests in relation to the ownership of coal mines in southwestern Siberia, extortion and illicit acquisitions of assets. Specifically, a recent report by Russian site www.versia.ru, which was based on an older report by British newspaper The Guardian, refers to Shchukin’s activities and to the suspicious routes of millions of euros from Russia to Britain, through companies with headquarters in Cyprus. It further notes that Shchukin would use illicit and unfair practices to blackmail his competitors, thus managing to bring coal mines under his control, which he would then transfer to Cypriot offshore companies. The Guardian brought details of the way Shchukin operated to light. According to the British newspaper, the former director of the “Gramoteyinskaya” and “Tagaryshskaya” mines, Igor Rudyk, was arrested on the unprecedented charge of… having an expired passport! After being detained for 24 days, Rudyk was informed that he was facing a five-year prison sentence. He later stated to The Guardian that they had offered to release him, with the condition that he would sign the concession of the coal mines. “I did it because I wanted to get out,” he stressed. According to the report, when the “Gramoteyinskaya” mine came into Shchukin’s possession, it was transferred to an offshore company in Cyprus, called “Cyrith Holding”. “All the Russian businessmen knew that London was the best place to have their money and Cyprus the best transit point for this cause,” said versia.ru. The same report makes extensive reference to the activities of people in Shchukin’s close family circle. Specifically, the husband of Shchukin’s daughter Elena, Ildar Uzbekov, son of a former senior executive of Russian energy giant “Gazprom”, appears to be the individual in charge of transferring the capital from Russia to Britain, via companies registered in Cyprus. “According to ancient Greek myth, the goddess Aphrodite was born on the island of Cyprus through the seafoam. Today, this myth has taken a different dimension: ‘dirty and criminal’ capital arrives from Russia to the island of Aphrodite. There it is laundered and then sent to the United Kingdom as clean money,” said versia.ru, adding that Shchukin, with the help of his son-in-law, transferred some €500 million to the United Kingdom through Cyprus. Under house arrest for bribery with a BMW X5 A different case of attempting to extract a coal mine was the reason that led to Alexander Shchukin’s arrest, when the company’s major shareholder Razrez Inskoy appealed to the Federal Authorities of Russia. Two deputy governors, the head of the district Crime Investigation Department, the investigator and Alexander Shchukin’s associates were arrested as well. According to a report by Russian newspaper Kommersant, Shchukin was charged with extortion and attempted bribery. In court he admitted to attempting to bribe the head of the district CID with a BMW X5 car. Today, he is under house arrest, while the Russian police appear to have applied to Interpol to investigate all of Shchukin’s offshore companies and bank accounts in Cyprus. While the uproar in the US over the moves of the former head of Donald Trump’s election campaign, Paul Manafort, via Cyprus continues with unabated vigour, the reports over the Shchukin case are intensifying concerns. Either way, the Republic’s Authorities have clarified that Cyprus has made all the necessary checks and signed agreements with foreign organisations for the best possible management of the phenomenon of tax evasion and money laundering. They also stress that Cyprus underwent strict checks in the era of the bailout memorandum, while it continues to report to the EU as well as the IMF as regards money laundering. The Central Bank said in an announcement that it assesses and supervises the implementation of the requirements of the relevant legal and regulatory framework for money laundering by the supervised institutions, based on international and European standards.


News Article | May 23, 2017
Site: www.pressat.co.uk

The activities of Russian oligarch Alexander Shchukin have thrown Cyprus into the whirlpool of international media. According to media reports, the Russian Authorities have asked, through Interpol, for details of Shchukin’s bank accounts and offshore companies, through which some €500 million appear to have been transferred from Russia to Britain. The international media have implicated the Russian tycoon, who is currently under house arrest, in cases of conflict of interests in relation to the ownership of coal mines in southwestern Siberia, extortion and illicit acquisitions of assets. Specifically, a recent report by Russian site www.versia.ru, which was based on an older report by British newspaper The Guardian, refers to Shchukin’s activities and to the suspicious routes of millions of euros from Russia to Britain, through companies with headquarters in Cyprus. It further notes that Shchukin would use illicit and unfair practices to blackmail his competitors, thus managing to bring coal mines under his control, which he would then transfer to Cypriot offshore companies. The Guardian brought details of the way Shchukin operated to light. According to the British newspaper, the former director of the “Gramoteyinskaya” and “Tagaryshskaya” mines, Igor Rudyk, was arrested on the unprecedented charge of… having an expired passport! After being detained for 24 days, Rudyk was informed that he was facing a five-year prison sentence. He later stated to The Guardian that they had offered to release him, with the condition that he would sign the concession of the coal mines. “I did it because I wanted to get out,” he stressed. According to the report, when the “Gramoteyinskaya” mine came into Shchukin’s possession, it was transferred to an offshore company in Cyprus, called “Cyrith Holding”. “All the Russian businessmen knew that London was the best place to have their money and Cyprus the best transit point for this cause,” said versia.ru. The same report makes extensive reference to the activities of people in Shchukin’s close family circle. Specifically, the husband of Shchukin’s daughter Elena, Ildar Uzbekov, son of a former senior executive of Russian energy giant “Gazprom”, appears to be the individual in charge of transferring the capital from Russia to Britain, via companies registered in Cyprus. “According to ancient Greek myth, the goddess Aphrodite was born on the island of Cyprus through the seafoam. Today, this myth has taken a different dimension: ‘dirty and criminal’ capital arrives from Russia to the island of Aphrodite. There it is laundered and then sent to the United Kingdom as clean money,” said versia.ru, adding that Shchukin, with the help of his son-in-law, transferred some €500 million to the United Kingdom through Cyprus. Under house arrest for bribery with a BMW X5 A different case of attempting to extract a coal mine was the reason that led to Alexander Shchukin’s arrest, when the company’s major shareholder Razrez Inskoy appealed to the Federal Authorities of Russia. Two deputy governors, the head of the district Crime Investigation Department, the investigator and Alexander Shchukin’s associates were arrested as well. According to a report by Russian newspaper Kommersant, Shchukin was charged with extortion and attempted bribery. In court he admitted to attempting to bribe the head of the district CID with a BMW X5 car. Today, he is under house arrest, while the Russian police appear to have applied to Interpol to investigate all of Shchukin’s offshore companies and bank accounts in Cyprus. While the uproar in the US over the moves of the former head of Donald Trump’s election campaign, Paul Manafort, via Cyprus continues with unabated vigour, the reports over the Shchukin case are intensifying concerns. Either way, the Republic’s Authorities have clarified that Cyprus has made all the necessary checks and signed agreements with foreign organisations for the best possible management of the phenomenon of tax evasion and money laundering. They also stress that Cyprus underwent strict checks in the era of the bailout memorandum, while it continues to report to the EU as well as the IMF as regards money laundering. The Central Bank said in an announcement that it assesses and supervises the implementation of the requirements of the relevant legal and regulatory framework for money laundering by the supervised institutions, based on international and European standards.


News Article | May 9, 2017
Site: www.businesswire.com

GREENVILLE, S.C.--(BUSINESS WIRE)--World Acceptance Corporation (NASDAQ: WRLD) today reported financial results for its fourth fiscal quarter and twelve months ended March 31, 2017. Net income for the fourth quarter increased 6.8% to $31.9 million compared to $29.8 million for the same quarter of the prior year. Net income per diluted share increased 6.4% to $3.64 in the fourth quarter of fiscal 2017 compared to $3.42 in the prior year quarter. Total revenues increased to $144.6 million for the fourth quarter of fiscal 2017, a 0.3% increase from the $144.1 million reported for the fourth quarter last year. Revenues from the 1,258 offices open throughout both quarterly periods increased by 1.3%. Interest and fee income decreased 1.6%, from $121.5 million in the fourth quarter of 2016 to $119.5 million in the fourth quarter of fiscal 2017 primarily due to a decrease in average earning loans and an unfavorable move in exchange rates. Insurance and other income increased by 10.6% to $25.1 million in the fourth quarter of fiscal 2017 compared with $22.7 million in the fourth quarter of fiscal 2016. The increase in other income was primarily due to an increase in tax preparation revenue of $2.7 million. The tax preparation business benefited from an interest and fee free tax advance loan offering to qualifying customers. This was offset by a $276,000 decrease in insurance revenue. Accounts in the US that were 61 days or more past due increased to 5.0% on a recency basis and to 7.0% on a contractual basis at March 31, 2017, compared to 4.4% and 6.5%, respectively, at March 31, 2016. On a consolidated basis, accounts that were 61 days or more past due increased to 5.5% on a recency basis and to 7.8% on a contractual basis at March 31, 2017, compared to 4.7% and 7.1%, respectively, at March 31, 2016. As a result of the higher delinquencies, our allowance to net loans increased from 9.0% at March 31, 2016, to 9.4% at March 31, 2017. As previously disclosed, the Company ceased all in-person collection visits effective December 18, 2015. During the fourth quarter of fiscal 2016, the Company experienced higher than normal delinquencies in January and February as well as higher than normal charge-offs, especially in the month of March, as accounts became more than 90 days past due. We continue to see elevated net charge-offs and delinquencies compared to historical levels, however we have seen an improvement in net charge-offs during the fourth quarter of fiscal 2017 compared to 2016. The provision for the quarter decreased $3.7 million when comparing the fourth quarter of fiscal 2017 to the fourth quarter of fiscal 2016. This is primarily due to a decrease in net charge-offs. Net charge-offs as a percentage of average net loans on an annualized basis decreased from 18.9% to 15.4% when comparing the two quarters. The prior year net charge-off rate benefited from the monthly sale of accounts previously charged-off totaling approximately $0.5 million. Consolidated net charge-offs excluding the impact of the charge-off sale were down $7.5 million when comparing the two fiscal quarters. The portion of the provision related to a change in loans outstanding decreased $1.7 million quarter over quarter due to gross loans outstanding decreasing $105.2 million in the fourth quarter of 2017 versus $152.2 million in the fourth quarter of 2016. Accounts 90 days past due in the US, which are fully reserved, decreased by $5.7 million in the current quarter versus $9.4 million the same quarter last year, which resulted in a $3.7 million increase in the provision. General and administrative expenses amounted to $70.0 million in the fourth fiscal quarter, a 5.2% increase over the $66.6 million in the same quarter of the prior fiscal year. As a percentage of revenues, G&A expenses increased from 46.2% during the fourth quarter of fiscal 2016 to 48.4% during the current quarter. G&A expenses per average open office increased by 6.6% when comparing the two fiscal quarters. G&A expense increased primarily due to an increase in personnel costs. Share based compensation increased $1.7 million during the quarter due to the release of expense previously accrued for the Group B performance based restricted stock awards in the fourth quarter of 2016. During the prior year quarter, the Company determined that the earnings per share target of $13.00 per share was not achievable during the measurement period which ended on March 31, 2017. Subsequently, the Compensation Committee of the Board of Directors, amended the awards allowing 25% of the Group B awards to vest for certain officers. The amendment resulted in a net $1.7 million reduction of compensation expense in the prior year quarter. The officers were required to forfeit their remaining Group B shares as a part of the amendment. Interest expense for the fourth quarter decreased $1.8 million compared to the fourth quarter of the prior year due to a 21.6% decrease in the average debt outstanding. The Company has reduced its outstanding debt by $79.5 million as of March 31, 2017, compared to March 31, 2016. This is a result of not repurchasing shares during the fiscal quarter as well as a decrease in loans outstanding. The Company’s fourth quarter effective income tax rate decreased to 34.6% compared with 35.5% in the prior year’s fourth quarter. Our effective tax rate benefitted from the settlement of a state tax matter subsequent to year end. Gross loans decreased to $1.06 billion as of March 31, 2017, a 0.7% decrease from the $1.07 billion of loans outstanding as of March 31, 2016. Gross loans in the US decreased 2.2%, and gross loans in Mexico increased 13.7% in US dollars. Gross loans in Mexico increased 23.5% in Mexican pesos. Gross loans in the US benefited from the acquisition of 14 branches and $18.9 million in gross loans during the quarter. The gross loan balance for the acquired branches was $18.3 million as of March 31, 2017. Without the acquisition, consolidated gross loans would have decreased 2.4% compared to prior year. Our unique borrowers in the US decreased by 62,039 or 7.8% during the fourth quarter of 2017. This is compared to a decrease of 88,172 or 10.8% in the fourth quarter of 2016 and a decrease of 73,180 or 8.6% in the fourth quarter of 2015. Year to date we have increased our unique customers in the US by 7,631 or 1.0%, compared to a decrease of 45,867 or 5.9% in fiscal 2016 and decrease of 11,914 or 1.5% in fiscal 2015. Other key return ratios for the fourth quarter included an 8.8% return on average assets and a return on average equity of 17.8% (both on a trailing 12-month basis). We remain optimistic about our Mexican operations. We have approximately 160,000 accounts and approximately $116.5 million in gross loans outstanding in Mexico. This represents a 13.7% increase in loan balances in US dollars over last year, and an increase of 23.5% in Mexican pesos over March 31, 2016. Annualized Mexican net charge-offs as a percent of average net loans decreased from 12.2% in fiscal 2016 to 10.0% during the current fiscal year. Additionally, our Mexican 61+ day delinquencies were 10.1% and 14.0% on a recency and contractual basis, respectively, as of March 31, 2017, a change from 7.3% and 12.3%, respectively, as of March 31, 2016. Excluding intercompany charges of $0.5 million in fiscal 2017 and $2.7 million in fiscal 2016, fiscal 2017 Mexican pretax earnings amounted to $8.5 million, a 3.6% increase from the $8.2 million in pretax earnings during fiscal 2016. For fiscal 2017, net income decreased 15.8% to $73.6 million compared with $87.4 million for the year ended March 31, 2016. Fully diluted net income per share decreased 16.6% to $8.38 in fiscal 2017 compared with $10.05 for fiscal 2016. Total revenues for fiscal 2017 declined 4.6% to $531.7 million compared with $557.5 million during fiscal 2016. Net charge-offs as a percent of average net loans increased from 14.8% during fiscal 2016 to 15.7% for fiscal 2017. Similar to the quarter, revenues were impacted by a decrease in average earning loans during the year. Net charge-offs for fiscal 2017 were negatively impacted by the cessation of in-person visits as discussed above. As previously disclosed, on August 7, 2015, the Company received a letter from the CFPB’s Enforcement Office notifying the Company that, in accordance with the CFPB’s discretionary Notice and Opportunity to Respond and Advise (“NORA”) process, the staff of CFPB’s Enforcement Office is considering recommending that the CFPB take legal action against the Company (the “NORA Letter”). The NORA Letter states that the staff of the CFPB’s Enforcement Office expects to allege that the Company violated the Consumer Financial Protection Act of 2010, 12 U.S.C. §5536. The NORA Letter confirms that the Company has the opportunity to make a NORA submission, which is a written statement setting forth any reasons of law or policy why the Company believes the CFPB should not take legal action against it. Following the CFPB’s NORA Letter, the Company made NORA submissions to the CFPB’s Enforcement Office. The Company understands that a NORA Letter is intended to ensure that potential subjects of enforcement actions have the opportunity to present their positions to the CFPB before an enforcement action is recommended or commenced. The Company continues to believe its historical and current business practices are lawful. World Acceptance Corporation is one of the largest small-loan consumer finance companies, operating 1,327 offices in 15 states and Mexico. It is also the parent company of ParaData Financial Systems, a provider of computer software solutions for the consumer finance industry. The senior management of World Acceptance Corporation will be discussing these results in its quarterly conference call to be held at 10:00 a.m. Eastern time today. A simulcast of the conference call will be available on the Internet at https://www.webcaster4.com/Webcast/Page/1118/20663. The call will be available for replay on the Internet for approximately 30 days. This press release may contain various “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, that represent the Company’s expectations or beliefs concerning future events. Statements other than those of historical fact, as well as those identified by the words “anticipate,” “estimate,” ”intend,” “plan,” “expect,” ”project,” “believe,” “may,” “will,” “should,” “would,” “could” and any variation of the foregoing and similar expressions are forward-looking statements. Such forward-looking statements are about matters that are inherently subject to risks and uncertainties. Factors that could cause actual results or performance to differ from the expectations expressed or implied in such forward-looking statements include the following: recently enacted, proposed or future legislation and the manner in which it is implemented; the nature and scope of regulatory authority, particularly discretionary authority, that may be exercised by regulators, including, but not limited to, the Consumer Financial Protection Bureau (the “CFPB”), having jurisdiction over the Company’s business or consumer financial transactions generically; the unpredictable nature of regulatory proceedings and litigation; any determinations, findings, claims or actions made or taken by the CFPB, other regulators or third parties that assert or establish that the Company’s lending practices or other aspects of its business violate applicable laws or regulations, which may or may not be in connection with or resulting from the previously disclosed civil investigative demand (CID) or the notice and opportunity to respond and advise (NORA) letter from the CFPB; the impact of changes in accounting rules and regulations, or their interpretation or application, which could materially and adversely affect the Company’s reported financial statements or necessitate material delays or changes in the issuance of the Company’s audited financial statements; the Company's assessment of its internal control over financial reporting, and the timing and effectiveness of the Company's efforts to remediate any reported material weakness in its internal control over financial reporting; changes in interest rates; risks related to expansion and foreign operations; risks inherent in making loans, including repayment risks and value of collateral; the timing and amount of revenues that may be recognized by the Company; changes in current revenue and expense trends (including trends affecting delinquencies and charge-offs); the potential impact of limitations in the Company’s amended revolving credit facility; and changes in the Company’s markets and general changes in the economy (particularly in the markets served by the Company). These and other factors are discussed in greater detail in Part I, Item 1A, “Risk Factors” in the Company’s most recent annual report on Form 10-K for the fiscal year ended March 31, 2016 filed with the Securities and Exchange Commission (“SEC”) and the Company’s other reports filed with, or furnished to, the SEC from time to time. World Acceptance Corporation does not undertake any obligation to update any forward-looking statements it makes. The Company is also not responsible for updating the information contained in this press release beyond the publication date, or for changes made to this document by wire services or Internet services.


News Article | May 8, 2017
Site: globenewswire.com

HOUSTON, May 08, 2017 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today reported financial results for the first quarter ended March 31, 2017 and provided an update on recent developments. “We had a productive first quarter across our pipeline,” said Rick Fair, Bellicum’s President & Chief Executive Officer. “We continued to make progress on the registration trial for BPX-501, and presented updated clinical data highlighting its potential to transform patients’ lives. We are actively recruiting initial clinical trials with our controllable CAR T and TCR product candidates, and presented preclinical data on exciting new enhancements to our pioneering technology platform. This progress underscores our commitment to developing novel cell therapies in areas of dire need.” BPX-501 Adjunct T-cell therapy, administered after allogeneic hematopoietic stem cell transplantation, to support faster immune recovery, improved infection control, and reduced mortality and Graft versus Host Disease (GvHD) BPX-601 Novel GoCAR-T™ product candidate designed with the proprietary iMC activation switch to improve efficacy Cash Position and Guidance: During the first quarter of 2017, Bellicum completed an underwritten public offering of common stock that provided approximately $64.6 million of net proceeds. Bellicum also borrowed the final $10.0 million tranche under its loan agreement with Hercules Capital. As of March 31, 2017, the Company had cash, restricted cash and investments totaling $164.6 million, compared to $113.4 million at December 31, 2016. Based on current operating plans, Bellicum expects to end 2017 with approximately $85 to $95 million in cash and investments, and that current cash resources will be sufficient to meet operating requirements through the end of 2018. Net Loss: Bellicum reported a net loss of $22.0 million for the first quarter of 2017, compared to a net loss of $15.1 million for the first quarter of 2016. The results included non-cash, share-based compensation charges of $3.4 million and $3.1 million for the first quarter of 2017 and 2016, respectively. R&D Expenses: Research and development expenses were $15.3 million and $10.9 million for the three months ended March 31, 2017 and 2016, respectively. The higher 2017 costs were due primarily to an additional $2.9 million of clinical development expenses for BPX-501 reflecting increased clinical trial activities and manufacturing costs due to increased enrollment in clinical trials, and an additional $1.5 million of expenses for increased personnel, overhead charges and manufacturing facility start-up costs. G&A Expenses: General and administrative expenses were $5.9 million for the three months ended March 31, 2017, and $4.3 million for the three months ended March 31, 2016. The increase in G&A expenses of $1.6 million in 2017, was due primarily to higher personnel costs as a result of hiring additional employees and to severance costs. About Bellicum Pharmaceuticals Bellicum is a clinical stage biopharmaceutical company focused on discovering and developing cellular immunotherapies for cancers and orphan inherited blood disorders. Bellicum is using its proprietary Chemical Induction of Dimerization (CID) technology platform to engineer and control components of the immune system. Bellicum is developing next-generation product candidates in some of the most important areas of cellular immunotherapy, including hematopoietic stem cell transplantation (HSCT), and CAR T and TCR cell therapies. More information can be found at www.bellicum.com. About BPX-501 BPX-501 is an adjunct T-cell therapy administered after allogeneic HSCT, comprising genetically modified donor T cells incorporating Bellicum’s CaspaCIDe® safety switch. It is designed to provide a safety net to eliminate alloreactive BPX-501 T cells (via administration of activator agent rimiducid) should uncontrollable GvHD occur. This enables physicians to more safely perform stem cell transplants by adding back BPX-501 engineered T cells to speed immune reconstitution and provide control over viral infections, without unacceptable risk of uncontrollable GvHD. The ongoing BP-004 Phase 1/2 clinical trial of BPX-501 is being conducted at transplant centers in the U.S. and Europe with pediatric patients with blood cancers and orphan inherited blood disorders. Forward-Looking Statement This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Bellicum may, in some cases, use terms such as "predicts," "believes," "potential," "proposed," "continue," “designed,” "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: our research and development activities relating to BPX-501, rimiducid, CaspaCIDe, dual switch, CAR-T and TCR programs; the effectiveness of BPX-501, its possible range of application and potential curative effects and safety in the treatment of diseases, including as compared to other treatment options and competitive therapies; the timing and success of our clinical trials, including comparator trials; the rate and progress of enrollment in our clinical trials for BPX-501, BPX-701 and BPX-601, including our planned registration trials for BPX-501 and rimiducid; the timing of regulatory filings for BPX-501 and rimiducid; our research and development activities relating to our GoCAR-T and GoTCR technologies; and, our expectations regarding our cash position. Various factors may cause differences between Bellicum’s expectations and actual results as discussed in greater detail under the heading “Risk Factors” in Bellicum’s filings with the Securities and Exchange Commission, including without limitation our annual report on Form 10-K for the year ended December 31, 2016 and our report on Form 10-Q for the quarter ended March 31, 2017. Any forward-looking statements that Bellicum makes in this press release speak only as of the date of this press release. Bellicum assumes no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.


News Article | May 8, 2017
Site: globenewswire.com

HOUSTON, May 08, 2017 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today reported financial results for the first quarter ended March 31, 2017 and provided an update on recent developments. “We had a productive first quarter across our pipeline,” said Rick Fair, Bellicum’s President & Chief Executive Officer. “We continued to make progress on the registration trial for BPX-501, and presented updated clinical data highlighting its potential to transform patients’ lives. We are actively recruiting initial clinical trials with our controllable CAR T and TCR product candidates, and presented preclinical data on exciting new enhancements to our pioneering technology platform. This progress underscores our commitment to developing novel cell therapies in areas of dire need.” BPX-501 Adjunct T-cell therapy, administered after allogeneic hematopoietic stem cell transplantation, to support faster immune recovery, improved infection control, and reduced mortality and Graft versus Host Disease (GvHD) BPX-601 Novel GoCAR-T™ product candidate designed with the proprietary iMC activation switch to improve efficacy Cash Position and Guidance: During the first quarter of 2017, Bellicum completed an underwritten public offering of common stock that provided approximately $64.6 million of net proceeds. Bellicum also borrowed the final $10.0 million tranche under its loan agreement with Hercules Capital. As of March 31, 2017, the Company had cash, restricted cash and investments totaling $164.6 million, compared to $113.4 million at December 31, 2016. Based on current operating plans, Bellicum expects to end 2017 with approximately $85 to $95 million in cash and investments, and that current cash resources will be sufficient to meet operating requirements through the end of 2018. Net Loss: Bellicum reported a net loss of $22.0 million for the first quarter of 2017, compared to a net loss of $15.1 million for the first quarter of 2016. The results included non-cash, share-based compensation charges of $3.4 million and $3.1 million for the first quarter of 2017 and 2016, respectively. R&D Expenses: Research and development expenses were $15.3 million and $10.9 million for the three months ended March 31, 2017 and 2016, respectively. The higher 2017 costs were due primarily to an additional $2.9 million of clinical development expenses for BPX-501 reflecting increased clinical trial activities and manufacturing costs due to increased enrollment in clinical trials, and an additional $1.5 million of expenses for increased personnel, overhead charges and manufacturing facility start-up costs. G&A Expenses: General and administrative expenses were $5.9 million for the three months ended March 31, 2017, and $4.3 million for the three months ended March 31, 2016. The increase in G&A expenses of $1.6 million in 2017, was due primarily to higher personnel costs as a result of hiring additional employees and to severance costs. About Bellicum Pharmaceuticals Bellicum is a clinical stage biopharmaceutical company focused on discovering and developing cellular immunotherapies for cancers and orphan inherited blood disorders. Bellicum is using its proprietary Chemical Induction of Dimerization (CID) technology platform to engineer and control components of the immune system. Bellicum is developing next-generation product candidates in some of the most important areas of cellular immunotherapy, including hematopoietic stem cell transplantation (HSCT), and CAR T and TCR cell therapies. More information can be found at www.bellicum.com. About BPX-501 BPX-501 is an adjunct T-cell therapy administered after allogeneic HSCT, comprising genetically modified donor T cells incorporating Bellicum’s CaspaCIDe® safety switch. It is designed to provide a safety net to eliminate alloreactive BPX-501 T cells (via administration of activator agent rimiducid) should uncontrollable GvHD occur. This enables physicians to more safely perform stem cell transplants by adding back BPX-501 engineered T cells to speed immune reconstitution and provide control over viral infections, without unacceptable risk of uncontrollable GvHD. The ongoing BP-004 Phase 1/2 clinical trial of BPX-501 is being conducted at transplant centers in the U.S. and Europe with pediatric patients with blood cancers and orphan inherited blood disorders. Forward-Looking Statement This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Bellicum may, in some cases, use terms such as "predicts," "believes," "potential," "proposed," "continue," “designed,” "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: our research and development activities relating to BPX-501, rimiducid, CaspaCIDe, dual switch, CAR-T and TCR programs; the effectiveness of BPX-501, its possible range of application and potential curative effects and safety in the treatment of diseases, including as compared to other treatment options and competitive therapies; the timing and success of our clinical trials, including comparator trials; the rate and progress of enrollment in our clinical trials for BPX-501, BPX-701 and BPX-601, including our planned registration trials for BPX-501 and rimiducid; the timing of regulatory filings for BPX-501 and rimiducid; our research and development activities relating to our GoCAR-T and GoTCR technologies; and, our expectations regarding our cash position. Various factors may cause differences between Bellicum’s expectations and actual results as discussed in greater detail under the heading “Risk Factors” in Bellicum’s filings with the Securities and Exchange Commission, including without limitation our annual report on Form 10-K for the year ended December 31, 2016 and our report on Form 10-Q for the quarter ended March 31, 2017. Any forward-looking statements that Bellicum makes in this press release speak only as of the date of this press release. Bellicum assumes no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.


News Article | May 8, 2017
Site: globenewswire.com

HOUSTON, May 08, 2017 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today reported financial results for the first quarter ended March 31, 2017 and provided an update on recent developments. “We had a productive first quarter across our pipeline,” said Rick Fair, Bellicum’s President & Chief Executive Officer. “We continued to make progress on the registration trial for BPX-501, and presented updated clinical data highlighting its potential to transform patients’ lives. We are actively recruiting initial clinical trials with our controllable CAR T and TCR product candidates, and presented preclinical data on exciting new enhancements to our pioneering technology platform. This progress underscores our commitment to developing novel cell therapies in areas of dire need.” BPX-501 Adjunct T-cell therapy, administered after allogeneic hematopoietic stem cell transplantation, to support faster immune recovery, improved infection control, and reduced mortality and Graft versus Host Disease (GvHD) BPX-601 Novel GoCAR-T™ product candidate designed with the proprietary iMC activation switch to improve efficacy Cash Position and Guidance: During the first quarter of 2017, Bellicum completed an underwritten public offering of common stock that provided approximately $64.6 million of net proceeds. Bellicum also borrowed the final $10.0 million tranche under its loan agreement with Hercules Capital. As of March 31, 2017, the Company had cash, restricted cash and investments totaling $164.6 million, compared to $113.4 million at December 31, 2016. Based on current operating plans, Bellicum expects to end 2017 with approximately $85 to $95 million in cash and investments, and that current cash resources will be sufficient to meet operating requirements through the end of 2018. Net Loss: Bellicum reported a net loss of $22.0 million for the first quarter of 2017, compared to a net loss of $15.1 million for the first quarter of 2016. The results included non-cash, share-based compensation charges of $3.4 million and $3.1 million for the first quarter of 2017 and 2016, respectively. R&D Expenses: Research and development expenses were $15.3 million and $10.9 million for the three months ended March 31, 2017 and 2016, respectively. The higher 2017 costs were due primarily to an additional $2.9 million of clinical development expenses for BPX-501 reflecting increased clinical trial activities and manufacturing costs due to increased enrollment in clinical trials, and an additional $1.5 million of expenses for increased personnel, overhead charges and manufacturing facility start-up costs. G&A Expenses: General and administrative expenses were $5.9 million for the three months ended March 31, 2017, and $4.3 million for the three months ended March 31, 2016. The increase in G&A expenses of $1.6 million in 2017, was due primarily to higher personnel costs as a result of hiring additional employees and to severance costs. About Bellicum Pharmaceuticals Bellicum is a clinical stage biopharmaceutical company focused on discovering and developing cellular immunotherapies for cancers and orphan inherited blood disorders. Bellicum is using its proprietary Chemical Induction of Dimerization (CID) technology platform to engineer and control components of the immune system. Bellicum is developing next-generation product candidates in some of the most important areas of cellular immunotherapy, including hematopoietic stem cell transplantation (HSCT), and CAR T and TCR cell therapies. More information can be found at www.bellicum.com. About BPX-501 BPX-501 is an adjunct T-cell therapy administered after allogeneic HSCT, comprising genetically modified donor T cells incorporating Bellicum’s CaspaCIDe® safety switch. It is designed to provide a safety net to eliminate alloreactive BPX-501 T cells (via administration of activator agent rimiducid) should uncontrollable GvHD occur. This enables physicians to more safely perform stem cell transplants by adding back BPX-501 engineered T cells to speed immune reconstitution and provide control over viral infections, without unacceptable risk of uncontrollable GvHD. The ongoing BP-004 Phase 1/2 clinical trial of BPX-501 is being conducted at transplant centers in the U.S. and Europe with pediatric patients with blood cancers and orphan inherited blood disorders. Forward-Looking Statement This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Bellicum may, in some cases, use terms such as "predicts," "believes," "potential," "proposed," "continue," “designed,” "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: our research and development activities relating to BPX-501, rimiducid, CaspaCIDe, dual switch, CAR-T and TCR programs; the effectiveness of BPX-501, its possible range of application and potential curative effects and safety in the treatment of diseases, including as compared to other treatment options and competitive therapies; the timing and success of our clinical trials, including comparator trials; the rate and progress of enrollment in our clinical trials for BPX-501, BPX-701 and BPX-601, including our planned registration trials for BPX-501 and rimiducid; the timing of regulatory filings for BPX-501 and rimiducid; our research and development activities relating to our GoCAR-T and GoTCR technologies; and, our expectations regarding our cash position. Various factors may cause differences between Bellicum’s expectations and actual results as discussed in greater detail under the heading “Risk Factors” in Bellicum’s filings with the Securities and Exchange Commission, including without limitation our annual report on Form 10-K for the year ended December 31, 2016 and our report on Form 10-Q for the quarter ended March 31, 2017. Any forward-looking statements that Bellicum makes in this press release speak only as of the date of this press release. Bellicum assumes no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.


News Article | May 8, 2017
Site: globenewswire.com

HOUSTON, May 08, 2017 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today reported financial results for the first quarter ended March 31, 2017 and provided an update on recent developments. “We had a productive first quarter across our pipeline,” said Rick Fair, Bellicum’s President & Chief Executive Officer. “We continued to make progress on the registration trial for BPX-501, and presented updated clinical data highlighting its potential to transform patients’ lives. We are actively recruiting initial clinical trials with our controllable CAR T and TCR product candidates, and presented preclinical data on exciting new enhancements to our pioneering technology platform. This progress underscores our commitment to developing novel cell therapies in areas of dire need.” BPX-501 Adjunct T-cell therapy, administered after allogeneic hematopoietic stem cell transplantation, to support faster immune recovery, improved infection control, and reduced mortality and Graft versus Host Disease (GvHD) BPX-601 Novel GoCAR-T™ product candidate designed with the proprietary iMC activation switch to improve efficacy Cash Position and Guidance: During the first quarter of 2017, Bellicum completed an underwritten public offering of common stock that provided approximately $64.6 million of net proceeds. Bellicum also borrowed the final $10.0 million tranche under its loan agreement with Hercules Capital. As of March 31, 2017, the Company had cash, restricted cash and investments totaling $164.6 million, compared to $113.4 million at December 31, 2016. Based on current operating plans, Bellicum expects to end 2017 with approximately $85 to $95 million in cash and investments, and that current cash resources will be sufficient to meet operating requirements through the end of 2018. Net Loss: Bellicum reported a net loss of $22.0 million for the first quarter of 2017, compared to a net loss of $15.1 million for the first quarter of 2016. The results included non-cash, share-based compensation charges of $3.4 million and $3.1 million for the first quarter of 2017 and 2016, respectively. R&D Expenses: Research and development expenses were $15.3 million and $10.9 million for the three months ended March 31, 2017 and 2016, respectively. The higher 2017 costs were due primarily to an additional $2.9 million of clinical development expenses for BPX-501 reflecting increased clinical trial activities and manufacturing costs due to increased enrollment in clinical trials, and an additional $1.5 million of expenses for increased personnel, overhead charges and manufacturing facility start-up costs. G&A Expenses: General and administrative expenses were $5.9 million for the three months ended March 31, 2017, and $4.3 million for the three months ended March 31, 2016. The increase in G&A expenses of $1.6 million in 2017, was due primarily to higher personnel costs as a result of hiring additional employees and to severance costs. About Bellicum Pharmaceuticals Bellicum is a clinical stage biopharmaceutical company focused on discovering and developing cellular immunotherapies for cancers and orphan inherited blood disorders. Bellicum is using its proprietary Chemical Induction of Dimerization (CID) technology platform to engineer and control components of the immune system. Bellicum is developing next-generation product candidates in some of the most important areas of cellular immunotherapy, including hematopoietic stem cell transplantation (HSCT), and CAR T and TCR cell therapies. More information can be found at www.bellicum.com. About BPX-501 BPX-501 is an adjunct T-cell therapy administered after allogeneic HSCT, comprising genetically modified donor T cells incorporating Bellicum’s CaspaCIDe® safety switch. It is designed to provide a safety net to eliminate alloreactive BPX-501 T cells (via administration of activator agent rimiducid) should uncontrollable GvHD occur. This enables physicians to more safely perform stem cell transplants by adding back BPX-501 engineered T cells to speed immune reconstitution and provide control over viral infections, without unacceptable risk of uncontrollable GvHD. The ongoing BP-004 Phase 1/2 clinical trial of BPX-501 is being conducted at transplant centers in the U.S. and Europe with pediatric patients with blood cancers and orphan inherited blood disorders. Forward-Looking Statement This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Bellicum may, in some cases, use terms such as "predicts," "believes," "potential," "proposed," "continue," “designed,” "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: our research and development activities relating to BPX-501, rimiducid, CaspaCIDe, dual switch, CAR-T and TCR programs; the effectiveness of BPX-501, its possible range of application and potential curative effects and safety in the treatment of diseases, including as compared to other treatment options and competitive therapies; the timing and success of our clinical trials, including comparator trials; the rate and progress of enrollment in our clinical trials for BPX-501, BPX-701 and BPX-601, including our planned registration trials for BPX-501 and rimiducid; the timing of regulatory filings for BPX-501 and rimiducid; our research and development activities relating to our GoCAR-T and GoTCR technologies; and, our expectations regarding our cash position. Various factors may cause differences between Bellicum’s expectations and actual results as discussed in greater detail under the heading “Risk Factors” in Bellicum’s filings with the Securities and Exchange Commission, including without limitation our annual report on Form 10-K for the year ended December 31, 2016 and our report on Form 10-Q for the quarter ended March 31, 2017. Any forward-looking statements that Bellicum makes in this press release speak only as of the date of this press release. Bellicum assumes no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

Loading CID collaborators
Loading CID collaborators